GLP-1

Novo inks $2.2B deal for Septerna's preclinical obesity programs

Novo offered more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Nick Paul Taylor May 14, 2025 7:00am

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

May 5, 2025 6:59pm

Ascletis sees no benefit to high, fast oral GLP-1 dose titration

Apr 23, 2025 7:25am

Ypsomed sells diabetes business to focus on GLP-1 self-injectors

Apr 23, 2025 6:20am

Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3

Apr 17, 2025 6:45am

Pfizer axes oral GLP-1 asset, blowing hole in obesity plan

Apr 14, 2025 7:34am